How a Drug Setback Became a Patient Community’s Gain

Ovid CEO Jeremy Levin and Angelman Syndrome Foundation CEO Amanda Moore discuss the LADDER database, Ovid’s decision to contribute its data to it, and why the two believe other drug developers should take similar steps to share their data with patients and researchers to advance the understanding of rare diseases.